Home
Alvotech

Alvotech Market Share Analysis for January 2026

we specialize in making biosimilars - to improve lives by expanding access to affordable biologic medicines.

Health > Biotechnology and Pharmaceuticals

Domainalvotech.com

Year Founded2013

Employees501 - 1000

Annual Revenue$200M - $500M

Alvotech

Alvotech (including company regionals)

alvotech.com

See more website traffic and engagement information

Alvotech Revenue up to January 2026 is 200M - 500M

revenue generated by Alvotech top domains

Alvotech top domains revenue over 3 years

Revenue for Alvotech top domains

alvotech.com200M - 500M

See more with Sales Intelligence

Alvotech Stock price in January 2026

Alvotech stock is traded under the ticker #ALVO. Below you can review Alvotech stock performance in the past 12 months up to January 2026

Total visits to Alvotech's top domains

Understand Alvotech market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

alvotech.com14.7K

See more with Sales Intelligence

Avg. visit duration in Alvotech's top domains

Analyze Alvotech engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

alvotech.com00:00:22

See more with Sales Intelligence

Avg. pageviews on Alvotech's top domains

See how Alvotech keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

alvotech.com1.78

See more with Sales Intelligence

Alvotech top competitors by domain

Top similar sites in January 2026, ranked by their affinity

alvogen.comCompany NameAlvogenEmployees1001 - 5000HQUnited States, New Jersey, MorristownAnnual revenue$500M - $1BTotal visits35KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Alvotech

These are the website technologies, by industry, used by Alvotech top domains

Conversion & Analytics (3)

Google Analytics

Email Services (3)

Microsoft Exchange Online

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

More Technologies

9

See all

News & Signals from Alvotech

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAlvotech is developing two biosimilars to Entyvio, AVT16 on Feb 5th '26.Alvotech is currently developing two biosimilars to Entyvio(R), AVT16 for intravenous administration, and AVT80 for subcutaneous administration.

NewsAlvotech partners with Sandoz.Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.

NewsAlvotech is developing AVT16, AVT10, AVT28, AVT48, AVT41, AVT65, and AVT19.In the immunology and gastroenterology fields, Alvotech has received approval for AVT05 (golimumab) in Japan, the UK and the EU and is developing AVT16 (vedolizumab), AVT10 (certolizumab pegol), AVT28 (ixekizumab), AVT48 (canakinumab), AVT41 (guselkumab), AVT65 (ofatumumab), and AVT19 (dupilumab).